Cure Today22d
FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC
It is the only ROS1 TKI with FDA breakthrough therapy designation for locally advanced or metastatic ROS1-positive NSCLC. The FDA has granted priority review to an NDA for taletrectinib in the ...
National Institute for Health and Care Excellence1mon
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
The appraisal committee has prepared final draft guidance (FDG) on crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) and submitted it to NICE. The FDG has ...
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight
Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...
Pharmabiz21d
China NMPA approves Innovent Biologics’ Dovbleron to treat ROS1-positive non-small cell lung cancer
In December 2024, Dovbleron was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC ... ROS1-positive NSCLC ...